We are interested in working with innovative industry partners and academic centers of excellence to progress the science and understanding of natural killer cells.
Our clear goal through such partnerships is ultimately to produce optimized natural killer cell therapeutics that will benefit cancer patients in need.
Partnership Opportunities
If you are interested in partnership opportunities please contact us.
Current Partnerships
We currently have several ongoing collaborations.
Academic Centers of Excellence
National Institutes of Health (NIH), Bethesda, MD, USA
Cooperative Research and Development Agreement (CRADA) covering the exploration of ex-vivo expanded natural killer cells to express death receptor 5 (DR5) specific tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) to augment cell-mediated killing of DR5 expressing tumors following adoptive cell immunotherapy.
VU University Medical Center (VUMC), Amsterdam, Netherlands
Research collaboration exploring the development and use of optimized affinity CD38 CAR-NK cells.
Xi’an Jiatong University, Shaanxi, China
Research programs exploring strategies to overcome micro-environmental mediated inhibition of natural killer cells.
Industry Partners
Our ONKT101 program, a dual-targeted NK cell therapy incorporating a CD19 CAR and TRAILv targeting the death receptor pathway (DR5) intended for the treatment of relapsed/refractory B cell malignancies, is partnered with Avectas and will utilize its proprietary SOLUPORETM technology as a means of non-viral genetic modification.
Seeking Partnerships
ONK Therapeutics is interested in forming additional partnership and collaborations, including the following areas:
Partnerships and collaboration
with biopharmaceutical companies to develop and commercialize optimized NK cell therapies.
Out-Licensing of ONK Therapeutics technologies
to enhance partner NK cell therapy approaches.
In-Licensing of technologies
to enhance our dual-targeted CAR-NK TRAILv platform.
Exploring potential combined therapeutic approaches
utilizing our cell therapy products with other anti-cancer therapies.
Partnership Opportunities
If you are interested in partnering with ONK Therapeutics, please contact us.
